Chronos' Deal With Shire Is 'Just The Start' Of Its Acquisitive New Strategy
Executive Summary
Chronos Therapeutics' acquisition of three preclinical central nervous system (CNS) disease-targeting assets from Shire PLC is the first of a possible series of deals the emerging biotech is seeking under its new business strategy.
You may also be interested in...
Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.